# Faro Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/faro-health

- Industry: Software
- Headquarters: San Diego, US
- Website: www.faro.ai/
- Total disclosed funding: $72M
- Latest round: Series B (Aug 26, 2026)
- Investors on record: 8

## About

Faro Health Inc. was founded in 2019 in San Diego, US, to provide digital solutions for clinical trials. In August 2026, Faro Health Inc. raised USD 37.3 million co-led by Merck Global Health Innovation Fund and Section 32, with participaton from Ankona Capital, General Catalyst Partners, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta Venture Partners. The company was co-founded by Ross Jaffe and Scott Chetham (CEO). 


Faro Health specializes in digital solutions for the clinical trial process, primarily through its flagship product, the Faro Study Designer. This AI-powered software enhances the efficiency and patient-friendliness of clinical trial protocol design, allowing teams to collaboratively develop and optimize protocols in real-time using data-driven insights and generative AI. Their solutions target biopharmaceutical companies and clinical research teams across North America and Europe, aiming to streamline trial processes and reduce costs.


Faro Health operates on a subscription-based revenue model, targeting business-to-business transactions with pharmaceutical and biotech companies. Clients typically engage in annual or multi-year contracts, gaining ongoing access to the Faro Study Designer and updates throughout the contract term. This model results in predictable revenue streams, allowing clients to utilize the software for various clinical trials while emphasizing AI-driven innovations that enhance operational efficiency.

The company will use the August 2026 funding to expand its AI capabilities and support wider deployment of AI agents across clinical development workflows.

## Funding rounds

- Series B, Aug 26, 2026, $37M — General Catalyst Partners, Polaris Partners, Merck Global Health Innovation Fund, Zetta Venture Partners, Section 32, Ankona Capital, Northpond Ventures, PTX Capital
- Series A, Jan 20, 2023, $20M — General Catalyst Partners, Polaris Partners, Zetta Venture Partners, Section 32, Northpond Ventures
- Series A, Jun 8, 2021, $15M — Polaris Partners, Zetta Venture Partners, Section 32, Northpond Ventures

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Zetta Venture Partners (https://capitalatlas.ai/funds/zetta-venture-partners) — Series A, Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A, Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B
- Ankona Capital (https://capitalatlas.ai/funds/ankona-capital) — Series B
- PTX Capital (https://capitalatlas.ai/funds/ptx-capital) — Series B